anti-CD3/anti-CD123 bispecific T-cell engager (Leidos Biomedical Research/Johns Hopkins University School of Medicine/University of Pittsburgh Medical Center)

N/A

Report date: 2025/06/11 10:34:59

Base Information

Drug Nameanti-CD3/anti-CD123 bispecific T-cell engager (Leidos Biomedical Research/Johns Hopkins University School of Medicine/University of Pittsburgh Medical Center)
Drug Alias NameN/A
ClassificationBiologics
Mechanisms of ActionT cell surface glycoprotein CD3 modulatorsInterleukin-3 receptor subunit alpha modulatorsImmunostimulants +[4] 
TargetsT cell surface glycoprotein CD3Interleukin-3 receptor subunit alpha
Therapy Area/IndicationsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesJohns Hopkins University School Of Medicine
China Registration ClassN/A

Develop Information

Active CompaniesLeidos Biomedical Research IncUniversity Of Pittsburgh Medical CenterJohns Hopkins University School Of Medicine
Inactive CompaniesN/A
Active IndicationsLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A